nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A2—Cisplatin—bone cancer	0.21	0.618	CbGbCtD
Amantadine—ABCB1—Cisplatin—bone cancer	0.0559	0.165	CbGbCtD
Amantadine—ABCB1—Doxorubicin—bone cancer	0.0374	0.11	CbGbCtD
Amantadine—ABCB1—Methotrexate—bone cancer	0.0363	0.107	CbGbCtD
Amantadine—GRIN2C—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0134	0.053	CbGpPWpGaD
Amantadine—GRIN2D—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0125	0.0493	CbGpPWpGaD
Amantadine—GRIN2A—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0102	0.0405	CbGpPWpGaD
Amantadine—GRIN1—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00892	0.0353	CbGpPWpGaD
Amantadine—GRIN2B—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00869	0.0344	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—FEV—bone cancer	0.00863	0.0342	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00742	0.0294	CbGpPWpGaD
Amantadine—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00464	0.0184	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00454	0.018	CbGpPWpGaD
Amantadine—DDC—Tryptophan metabolism—CYP3A4—bone cancer	0.00454	0.018	CbGpPWpGaD
Amantadine—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00449	0.0178	CbGpPWpGaD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00432	0.0171	CbGpPWpGaD
Amantadine—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.0042	0.0166	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00419	0.0166	CbGpPWpGaD
Amantadine—GRIN1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00414	0.0164	CbGpPWpGaD
Amantadine—DRD2—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00409	0.0162	CbGpPWpGaD
Amantadine—GRIN2C—Post NMDA receptor activation events—BRAF—bone cancer	0.00382	0.0151	CbGpPWpGaD
Amantadine—MAOB—Tryptophan metabolism—CYP3A4—bone cancer	0.00382	0.0151	CbGpPWpGaD
Amantadine—Keratitis—Doxorubicin—bone cancer	0.00367	0.00899	CcSEcCtD
Amantadine—GRIN2D—Post NMDA receptor activation events—BRAF—bone cancer	0.00355	0.0141	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00354	0.014	CbGpPWpGaD
Amantadine—Hypokinesia—Doxorubicin—bone cancer	0.00353	0.00864	CcSEcCtD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00352	0.0139	CbGpPWpGaD
Amantadine—Irritability—Cisplatin—bone cancer	0.00347	0.0085	CcSEcCtD
Amantadine—Paralysis—Doxorubicin—bone cancer	0.00343	0.00839	CcSEcCtD
Amantadine—Orthostatic hypotension—Cisplatin—bone cancer	0.00332	0.00814	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00327	0.013	CbGpPWpGaD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00309	0.0122	CbGpPWpGaD
Amantadine—Sweating increased—Cisplatin—bone cancer	0.00306	0.0075	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00301	0.0119	CbGpPWpGaD
Amantadine—Delirium—Epirubicin—bone cancer	0.00299	0.00733	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—BRAF—bone cancer	0.00292	0.0116	CbGpPWpGaD
Amantadine—Dysarthria—Methotrexate—bone cancer	0.00291	0.00712	CcSEcCtD
Amantadine—Delirium—Doxorubicin—bone cancer	0.00277	0.00678	CcSEcCtD
Amantadine—Dyskinesia—Epirubicin—bone cancer	0.00274	0.00671	CcSEcCtD
Amantadine—Dysarthria—Epirubicin—bone cancer	0.00272	0.00666	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00269	0.0106	CbGpPWpGaD
Amantadine—Depressed level of consciousness—Methotrexate—bone cancer	0.00265	0.0065	CcSEcCtD
Amantadine—Gait disturbance—Epirubicin—bone cancer	0.00264	0.00646	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—BRAF—bone cancer	0.00254	0.0101	CbGpPWpGaD
Amantadine—Dyskinesia—Doxorubicin—bone cancer	0.00253	0.00621	CcSEcCtD
Amantadine—Dysarthria—Doxorubicin—bone cancer	0.00252	0.00617	CcSEcCtD
Amantadine—Coma—Methotrexate—bone cancer	0.00251	0.00615	CcSEcCtD
Amantadine—MAOB—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.0025	0.00991	CbGpPWpGaD
Amantadine—Urinary tract disorder—Cisplatin—bone cancer	0.00248	0.00609	CcSEcCtD
Amantadine—GRIN2B—Post NMDA receptor activation events—BRAF—bone cancer	0.00248	0.00983	CbGpPWpGaD
Amantadine—Urethral disorder—Cisplatin—bone cancer	0.00247	0.00604	CcSEcCtD
Amantadine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00245	0.00972	CbGpPWpGaD
Amantadine—Pulmonary oedema—Methotrexate—bone cancer	0.00245	0.00599	CcSEcCtD
Amantadine—Gait disturbance—Doxorubicin—bone cancer	0.00244	0.00598	CcSEcCtD
Amantadine—Visual impairment—Cisplatin—bone cancer	0.00242	0.00594	CcSEcCtD
Amantadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00241	0.00956	CbGpPWpGaD
Amantadine—Eye disorder—Cisplatin—bone cancer	0.00235	0.00576	CcSEcCtD
Amantadine—Coma—Epirubicin—bone cancer	0.00235	0.00576	CcSEcCtD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00234	0.00928	CbGpPWpGaD
Amantadine—Cardiac disorder—Cisplatin—bone cancer	0.00233	0.00572	CcSEcCtD
Amantadine—Pulmonary oedema—Epirubicin—bone cancer	0.00229	0.00561	CcSEcCtD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00228	0.00905	CbGpPWpGaD
Amantadine—Photosensitivity—Methotrexate—bone cancer	0.00227	0.00557	CcSEcCtD
Amantadine—Mediastinal disorder—Cisplatin—bone cancer	0.00227	0.00555	CcSEcCtD
Amantadine—Hypertonia—Epirubicin—bone cancer	0.00226	0.00552	CcSEcCtD
Amantadine—Arrhythmia—Cisplatin—bone cancer	0.00225	0.00551	CcSEcCtD
Amantadine—Mental disability—Epirubicin—bone cancer	0.00223	0.00547	CcSEcCtD
Amantadine—Alopecia—Cisplatin—bone cancer	0.00222	0.00545	CcSEcCtD
Amantadine—Malnutrition—Cisplatin—bone cancer	0.00219	0.00537	CcSEcCtD
Amantadine—Coma—Doxorubicin—bone cancer	0.00218	0.00533	CcSEcCtD
Amantadine—GRIN2B—ErbB4 signaling events—MDM2—bone cancer	0.00217	0.00861	CbGpPWpGaD
Amantadine—Renal failure acute—Methotrexate—bone cancer	0.00216	0.0053	CcSEcCtD
Amantadine—Photosensitivity—Epirubicin—bone cancer	0.00213	0.00521	CcSEcCtD
Amantadine—Pulmonary oedema—Doxorubicin—bone cancer	0.00212	0.00519	CcSEcCtD
Amantadine—Visual disturbance—Methotrexate—bone cancer	0.00211	0.00516	CcSEcCtD
Amantadine—Hypertonia—Doxorubicin—bone cancer	0.00209	0.00511	CcSEcCtD
Amantadine—DDC—Tryptophan metabolism—MDM2—bone cancer	0.00208	0.00826	CbGpPWpGaD
Amantadine—Eczema—Epirubicin—bone cancer	0.00208	0.00509	CcSEcCtD
Amantadine—Mental disability—Doxorubicin—bone cancer	0.00207	0.00506	CcSEcCtD
Amantadine—Vision blurred—Cisplatin—bone cancer	0.00206	0.00506	CcSEcCtD
Amantadine—Cardiac failure congestive—Epirubicin—bone cancer	0.00206	0.00505	CcSEcCtD
Amantadine—Tremor—Cisplatin—bone cancer	0.00205	0.00503	CcSEcCtD
Amantadine—Lethargy—Methotrexate—bone cancer	0.00204	0.00499	CcSEcCtD
Amantadine—Renal failure acute—Epirubicin—bone cancer	0.00202	0.00496	CcSEcCtD
Amantadine—Osteoarthritis—Methotrexate—bone cancer	0.002	0.00489	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—EIF2S1—bone cancer	0.00198	0.00783	CbGpPWpGaD
Amantadine—Photosensitivity—Doxorubicin—bone cancer	0.00197	0.00482	CcSEcCtD
Amantadine—Leukopenia—Cisplatin—bone cancer	0.00196	0.0048	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—EIF2S1—bone cancer	0.00193	0.00764	CbGpPWpGaD
Amantadine—Eczema—Doxorubicin—bone cancer	0.00192	0.00471	CcSEcCtD
Amantadine—Cardiac failure—Epirubicin—bone cancer	0.00191	0.00469	CcSEcCtD
Amantadine—Lethargy—Epirubicin—bone cancer	0.00191	0.00467	CcSEcCtD
Amantadine—Cardiac failure congestive—Doxorubicin—bone cancer	0.00191	0.00467	CcSEcCtD
Amantadine—Irritability—Methotrexate—bone cancer	0.0019	0.00467	CcSEcCtD
Amantadine—Convulsion—Cisplatin—bone cancer	0.0019	0.00465	CcSEcCtD
Amantadine—Ataxia—Methotrexate—bone cancer	0.00188	0.0046	CcSEcCtD
Amantadine—Renal failure acute—Doxorubicin—bone cancer	0.00187	0.00459	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—bone cancer	0.00187	0.00458	CcSEcCtD
Amantadine—Anxiety—Cisplatin—bone cancer	0.00186	0.00455	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00185	0.00454	CcSEcCtD
Amantadine—Liver function test abnormal—Methotrexate—bone cancer	0.00184	0.00451	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00179	0.00709	CbGpPWpGaD
Amantadine—Anaphylactic shock—Cisplatin—bone cancer	0.00179	0.00438	CcSEcCtD
Amantadine—Oedema—Cisplatin—bone cancer	0.00179	0.00438	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—bone cancer	0.00178	0.00435	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—bone cancer	0.00177	0.00434	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—bone cancer	0.00176	0.00432	CcSEcCtD
Amantadine—Ataxia—Epirubicin—bone cancer	0.00176	0.0043	CcSEcCtD
Amantadine—MAOB—Tryptophan metabolism—MDM2—bone cancer	0.00175	0.00695	CbGpPWpGaD
Amantadine—Nervous system disorder—Cisplatin—bone cancer	0.00175	0.00429	CcSEcCtD
Amantadine—Tachycardia—Cisplatin—bone cancer	0.00174	0.00427	CcSEcCtD
Amantadine—Skin disorder—Cisplatin—bone cancer	0.00174	0.00425	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—bone cancer	0.00173	0.00423	CcSEcCtD
Amantadine—Hyperhidrosis—Cisplatin—bone cancer	0.00173	0.00423	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—bone cancer	0.00172	0.00422	CcSEcCtD
Amantadine—Orthostatic hypotension—Epirubicin—bone cancer	0.00171	0.00418	CcSEcCtD
Amantadine—Anorexia—Cisplatin—bone cancer	0.0017	0.00417	CcSEcCtD
Amantadine—Hypotension—Cisplatin—bone cancer	0.00167	0.00409	CcSEcCtD
Amantadine—Cardiac arrest—Doxorubicin—bone cancer	0.00164	0.00403	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—bone cancer	0.00162	0.00398	CcSEcCtD
Amantadine—Dysphagia—Epirubicin—bone cancer	0.00161	0.00395	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—bone cancer	0.00161	0.00395	CcSEcCtD
Amantadine—Paraesthesia—Cisplatin—bone cancer	0.00161	0.00393	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—bone cancer	0.0016	0.00391	CcSEcCtD
Amantadine—Dyspnoea—Cisplatin—bone cancer	0.00159	0.0039	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—bone cancer	0.00158	0.00387	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—bone cancer	0.00157	0.00386	CcSEcCtD
Amantadine—Decreased appetite—Cisplatin—bone cancer	0.00155	0.00381	CcSEcCtD
Amantadine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00154	0.00378	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—GNA11—bone cancer	0.00154	0.00609	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—EZH2—bone cancer	0.00153	0.00606	CbGpPWpGaD
Amantadine—Neutropenia—Epirubicin—bone cancer	0.00151	0.0037	CcSEcCtD
Amantadine—Dysphagia—Doxorubicin—bone cancer	0.00149	0.00366	CcSEcCtD
Amantadine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00148	0.00586	CbGpPWpGaD
Amantadine—Photosensitivity reaction—Epirubicin—bone cancer	0.00147	0.00361	CcSEcCtD
Amantadine—Feeling abnormal—Cisplatin—bone cancer	0.00147	0.00361	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—bone cancer	0.00144	0.00352	CcSEcCtD
Amantadine—Body temperature increased—Cisplatin—bone cancer	0.00141	0.00346	CcSEcCtD
Amantadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00141	0.00558	CbGpPWpGaD
Amantadine—Neutropenia—Doxorubicin—bone cancer	0.0014	0.00342	CcSEcCtD
Amantadine—Urinary tract disorder—Methotrexate—bone cancer	0.00136	0.00334	CcSEcCtD
Amantadine—Photosensitivity reaction—Doxorubicin—bone cancer	0.00136	0.00334	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—bone cancer	0.00135	0.00332	CcSEcCtD
Amantadine—Agranulocytosis—Epirubicin—bone cancer	0.00134	0.00329	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—bone cancer	0.00133	0.00326	CcSEcCtD
Amantadine—MAOB—Biological oxidations—CYP3A4—bone cancer	0.00133	0.00527	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00132	0.00522	CbGpPWpGaD
Amantadine—Hypersensitivity—Cisplatin—bone cancer	0.00132	0.00323	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—bone cancer	0.00129	0.00316	CcSEcCtD
Amantadine—Asthenia—Cisplatin—bone cancer	0.00128	0.00314	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—bone cancer	0.00128	0.00314	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—bone cancer	0.00128	0.00313	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—bone cancer	0.00127	0.00312	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—bone cancer	0.00127	0.0031	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—bone cancer	0.00125	0.00307	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—bone cancer	0.00125	0.00305	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—bone cancer	0.00124	0.00305	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—bone cancer	0.00124	0.00304	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00123	0.00485	CbGpPWpGaD
Amantadine—Diarrhoea—Cisplatin—bone cancer	0.00122	0.003	CcSEcCtD
Amantadine—Alopecia—Methotrexate—bone cancer	0.00122	0.00299	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—bone cancer	0.00121	0.00296	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—bone cancer	0.00121	0.00296	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—bone cancer	0.0012	0.00294	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—bone cancer	0.0012	0.00294	CcSEcCtD
Amantadine—Urinary tract disorder—Doxorubicin—bone cancer	0.00118	0.00289	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—bone cancer	0.00118	0.00289	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—bone cancer	0.00117	0.00287	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—bone cancer	0.00117	0.00287	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—bone cancer	0.00116	0.00285	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—bone cancer	0.00115	0.00283	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—bone cancer	0.00115	0.00282	CcSEcCtD
Amantadine—Alopecia—Epirubicin—bone cancer	0.00114	0.0028	CcSEcCtD
Amantadine—GRIN1—EPH-Ephrin signaling—MMP2—bone cancer	0.00114	0.00451	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CDK4—bone cancer	0.00114	0.0045	CbGpPWpGaD
Amantadine—MAOB—Biological oxidations—GSTP1—bone cancer	0.00114	0.0045	CbGpPWpGaD
Amantadine—Vomiting—Cisplatin—bone cancer	0.00114	0.00278	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—bone cancer	0.00113	0.00277	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—bone cancer	0.00113	0.00277	CcSEcCtD
Amantadine—Rash—Cisplatin—bone cancer	0.00113	0.00276	CcSEcCtD
Amantadine—Dermatitis—Cisplatin—bone cancer	0.00113	0.00276	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—bone cancer	0.00112	0.00276	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—bone cancer	0.00112	0.00274	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—bone cancer	0.00111	0.00272	CcSEcCtD
Amantadine—GRIN2B—EPH-Ephrin signaling—MMP2—bone cancer	0.00111	0.00439	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.0011	0.00437	CbGpPWpGaD
Amantadine—Tension—Epirubicin—bone cancer	0.0011	0.0027	CcSEcCtD
Amantadine—Nervousness—Epirubicin—bone cancer	0.00109	0.00268	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—bone cancer	0.00108	0.00266	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—bone cancer	0.00108	0.00264	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—bone cancer	0.00108	0.00264	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—bone cancer	0.00107	0.00262	CcSEcCtD
Amantadine—Nausea—Cisplatin—bone cancer	0.00106	0.0026	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—bone cancer	0.00106	0.0026	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—bone cancer	0.00106	0.00259	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—bone cancer	0.00105	0.00257	CcSEcCtD
Amantadine—Convulsion—Methotrexate—bone cancer	0.00104	0.00255	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—bone cancer	0.00104	0.00255	CcSEcCtD
Amantadine—Agitation—Epirubicin—bone cancer	0.00103	0.00253	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00103	0.00407	CbGpPWpGaD
Amantadine—Tension—Doxorubicin—bone cancer	0.00102	0.0025	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00102	0.00249	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—bone cancer	0.00101	0.00248	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—bone cancer	0.00101	0.00247	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00101	0.00399	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—bone cancer	0.001	0.00397	CbGpPWpGaD
Amantadine—Palpitations—Epirubicin—bone cancer	0.000994	0.00243	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—BRAF—bone cancer	0.000991	0.00392	CbGpPWpGaD
Amantadine—Confusional state—Methotrexate—bone cancer	0.000989	0.00242	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—RB1—bone cancer	0.000989	0.00392	CbGpPWpGaD
Amantadine—Anaphylactic shock—Methotrexate—bone cancer	0.000981	0.0024	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—bone cancer	0.000981	0.0024	CcSEcCtD
Amantadine—Convulsion—Epirubicin—bone cancer	0.000974	0.00239	CcSEcCtD
Amantadine—Hypertension—Epirubicin—bone cancer	0.000971	0.00238	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—bone cancer	0.000962	0.00236	CcSEcCtD
Amantadine—DRD2—G alpha (i) signalling events—RGS1—bone cancer	0.000957	0.00379	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—GRM4—bone cancer	0.000957	0.00379	CbGpPWpGaD
Amantadine—Agitation—Doxorubicin—bone cancer	0.000956	0.00234	CcSEcCtD
Amantadine—Anxiety—Epirubicin—bone cancer	0.000954	0.00234	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—bone cancer	0.000953	0.00233	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000951	0.00233	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—bone cancer	0.000948	0.00232	CcSEcCtD
Amantadine—DDC—Metabolism—NDUFA12—bone cancer	0.000947	0.00375	CbGpPWpGaD
Amantadine—Dry mouth—Epirubicin—bone cancer	0.000936	0.00229	CcSEcCtD
Amantadine—Anorexia—Methotrexate—bone cancer	0.000935	0.00229	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—bone cancer	0.000932	0.00228	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—bone cancer	0.000931	0.00369	CbGpPWpGaD
Amantadine—Confusional state—Epirubicin—bone cancer	0.000926	0.00227	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—BRAF—bone cancer	0.000921	0.00365	CbGpPWpGaD
Amantadine—Palpitations—Doxorubicin—bone cancer	0.00092	0.00225	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—bone cancer	0.000918	0.00225	CcSEcCtD
Amantadine—Oedema—Epirubicin—bone cancer	0.000918	0.00225	CcSEcCtD
Amantadine—Hypotension—Methotrexate—bone cancer	0.000917	0.00225	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—bone cancer	0.000902	0.00221	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—bone cancer	0.0009	0.00221	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—bone cancer	0.000898	0.0022	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—bone cancer	0.000896	0.00219	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—bone cancer	0.000892	0.00218	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—bone cancer	0.000887	0.00217	CcSEcCtD
Amantadine—Insomnia—Methotrexate—bone cancer	0.000887	0.00217	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—bone cancer	0.000883	0.00216	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—bone cancer	0.000881	0.00216	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00088	0.00216	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000878	0.00348	CbGpPWpGaD
Amantadine—Anorexia—Epirubicin—bone cancer	0.000875	0.00214	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—bone cancer	0.000874	0.00214	CcSEcCtD
Amantadine—Somnolence—Methotrexate—bone cancer	0.000872	0.00214	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—bone cancer	0.000866	0.00212	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—CDK4—bone cancer	0.000864	0.00342	CbGpPWpGaD
Amantadine—Dyspepsia—Methotrexate—bone cancer	0.000863	0.00212	CcSEcCtD
Amantadine—Hypotension—Epirubicin—bone cancer	0.000858	0.0021	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—bone cancer	0.000856	0.0021	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000855	0.00339	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—MMP9—bone cancer	0.000855	0.00339	CbGpPWpGaD
Amantadine—Decreased appetite—Methotrexate—bone cancer	0.000853	0.00209	CcSEcCtD
Amantadine—Oedema—Doxorubicin—bone cancer	0.000849	0.00208	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—bone cancer	0.000849	0.00208	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000847	0.00207	CcSEcCtD
Amantadine—Fatigue—Methotrexate—bone cancer	0.000846	0.00207	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000843	0.00334	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—MMP9—bone cancer	0.000834	0.0033	CbGpPWpGaD
Amantadine—Nervous system disorder—Doxorubicin—bone cancer	0.000833	0.00204	CcSEcCtD
Amantadine—Insomnia—Epirubicin—bone cancer	0.00083	0.00203	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—MDM2—bone cancer	0.00083	0.00329	CbGpPWpGaD
Amantadine—Tachycardia—Doxorubicin—bone cancer	0.000829	0.00203	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—bone cancer	0.000825	0.00202	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—bone cancer	0.000824	0.00202	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—bone cancer	0.000821	0.00201	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—bone cancer	0.000818	0.002	CcSEcCtD
Amantadine—Somnolence—Epirubicin—bone cancer	0.000816	0.002	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—PTGS2—bone cancer	0.000813	0.00322	CbGpPWpGaD
Amantadine—Anorexia—Doxorubicin—bone cancer	0.00081	0.00198	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—bone cancer	0.000808	0.00198	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—bone cancer	0.000808	0.00198	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—bone cancer	0.000798	0.00195	CcSEcCtD
Amantadine—MAOB—Metabolism—NDUFA12—bone cancer	0.000797	0.00316	CbGpPWpGaD
Amantadine—Hypotension—Doxorubicin—bone cancer	0.000794	0.00194	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000792	0.00194	CcSEcCtD
Amantadine—Fatigue—Epirubicin—bone cancer	0.000791	0.00194	CcSEcCtD
Amantadine—Constipation—Epirubicin—bone cancer	0.000785	0.00192	CcSEcCtD
Amantadine—DDC—Metabolism—NT5C3A—bone cancer	0.000784	0.00311	CbGpPWpGaD
Amantadine—Body temperature increased—Methotrexate—bone cancer	0.000775	0.0019	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—MDM2—bone cancer	0.000772	0.00306	CbGpPWpGaD
Amantadine—Insomnia—Doxorubicin—bone cancer	0.000768	0.00188	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000764	0.00303	CbGpPWpGaD
Amantadine—Paraesthesia—Doxorubicin—bone cancer	0.000763	0.00187	CcSEcCtD
Amantadine—GRIN2C—Neuronal System—BRAF—bone cancer	0.000759	0.00301	CbGpPWpGaD
Amantadine—Dyspnoea—Doxorubicin—bone cancer	0.000757	0.00186	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—bone cancer	0.000756	0.00185	CcSEcCtD
Amantadine—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.000756	0.003	CbGpPWpGaD
Amantadine—Somnolence—Doxorubicin—bone cancer	0.000755	0.00185	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—bone cancer	0.000748	0.00183	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—bone cancer	0.000738	0.00181	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000735	0.00291	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000733	0.0018	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—bone cancer	0.000732	0.00179	CcSEcCtD
Amantadine—Constipation—Doxorubicin—bone cancer	0.000726	0.00178	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—bone cancer	0.000726	0.00178	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—bone cancer	0.000723	0.00177	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000717	0.00284	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MMP9—bone cancer	0.000713	0.00282	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—BRAF—bone cancer	0.000706	0.0028	CbGpPWpGaD
Amantadine—Asthenia—Methotrexate—bone cancer	0.000704	0.00172	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—bone cancer	0.0007	0.00171	CcSEcCtD
Amantadine—Pruritus—Methotrexate—bone cancer	0.000694	0.0017	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—JUN—bone cancer	0.000682	0.0027	CbGpPWpGaD
Amantadine—Hypersensitivity—Epirubicin—bone cancer	0.000676	0.00166	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—bone cancer	0.000671	0.00164	CcSEcCtD
Amantadine—Diarrhoea—Methotrexate—bone cancer	0.000671	0.00164	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—TP53—bone cancer	0.000667	0.00264	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NT5C3A—bone cancer	0.00066	0.00262	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—BRAF—bone cancer	0.00066	0.00261	CbGpPWpGaD
Amantadine—Asthenia—Epirubicin—bone cancer	0.000659	0.00161	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—TP53—bone cancer	0.00065	0.00257	CbGpPWpGaD
Amantadine—Pruritus—Epirubicin—bone cancer	0.000649	0.00159	CcSEcCtD
Amantadine—Dizziness—Methotrexate—bone cancer	0.000649	0.00159	CcSEcCtD
Amantadine—GRIN2B—Transmission across Chemical Synapses—BRAF—bone cancer	0.000643	0.00255	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—MDM2—bone cancer	0.000636	0.00252	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	0.000634	0.00251	CbGpPWpGaD
Amantadine—Diarrhoea—Epirubicin—bone cancer	0.000628	0.00154	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—bone cancer	0.000626	0.00153	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—JUN—bone cancer	0.000625	0.00248	CbGpPWpGaD
Amantadine—Vomiting—Methotrexate—bone cancer	0.000624	0.00153	CcSEcCtD
Amantadine—Rash—Methotrexate—bone cancer	0.000618	0.00152	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—bone cancer	0.000618	0.00151	CcSEcCtD
Amantadine—Headache—Methotrexate—bone cancer	0.000614	0.00151	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000614	0.00243	CbGpPWpGaD
Amantadine—Asthenia—Doxorubicin—bone cancer	0.000609	0.00149	CcSEcCtD
Amantadine—GRIN2B—BDNF signaling pathway—JUN—bone cancer	0.000609	0.00241	CbGpPWpGaD
Amantadine—Dizziness—Epirubicin—bone cancer	0.000607	0.00149	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—GNA11—bone cancer	0.000606	0.0024	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EZH2—bone cancer	0.000604	0.00239	CbGpPWpGaD
Amantadine—Pruritus—Doxorubicin—bone cancer	0.000601	0.00147	CcSEcCtD
Amantadine—GRIN2D—Neuronal System—MDM2—bone cancer	0.000591	0.00234	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000586	0.00232	CbGpPWpGaD
Amantadine—Vomiting—Epirubicin—bone cancer	0.000584	0.00143	CcSEcCtD
Amantadine—Nausea—Methotrexate—bone cancer	0.000583	0.00143	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—bone cancer	0.000581	0.00142	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—GRM4—bone cancer	0.00058	0.0023	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—BRAF—bone cancer	0.000579	0.0023	CbGpPWpGaD
Amantadine—Rash—Epirubicin—bone cancer	0.000579	0.00142	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—bone cancer	0.000578	0.00142	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—EGFR—bone cancer	0.000576	0.00228	CbGpPWpGaD
Amantadine—Headache—Epirubicin—bone cancer	0.000575	0.00141	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—bone cancer	0.000562	0.00138	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—JUN—bone cancer	0.000557	0.00221	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000553	0.00219	CbGpPWpGaD
Amantadine—Nausea—Epirubicin—bone cancer	0.000545	0.00134	CcSEcCtD
Amantadine—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000541	0.00214	CbGpPWpGaD
Amantadine—Vomiting—Doxorubicin—bone cancer	0.00054	0.00132	CcSEcCtD
Amantadine—GRIN2B—Transmission across Chemical Synapses—MDM2—bone cancer	0.000539	0.00213	CbGpPWpGaD
Amantadine—Rash—Doxorubicin—bone cancer	0.000536	0.00131	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—bone cancer	0.000535	0.00131	CcSEcCtD
Amantadine—Headache—Doxorubicin—bone cancer	0.000532	0.0013	CcSEcCtD
Amantadine—GRIN1—Axon guidance—MET—bone cancer	0.000507	0.00201	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—BRAF—bone cancer	0.000505	0.002	CbGpPWpGaD
Amantadine—Nausea—Doxorubicin—bone cancer	0.000504	0.00124	CcSEcCtD
Amantadine—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000504	0.002	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—GRM1—bone cancer	0.000503	0.00199	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000503	0.00199	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MET—bone cancer	0.000494	0.00196	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—BRAF—bone cancer	0.000493	0.00195	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—MDM2—bone cancer	0.000486	0.00192	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—bone cancer	0.000484	0.00192	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000467	0.00185	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000435	0.00172	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000427	0.00169	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—MDM2—bone cancer	0.000424	0.00168	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NDUFA12—bone cancer	0.000423	0.00167	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MMP2—bone cancer	0.000423	0.00167	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—MDM2—bone cancer	0.000413	0.00164	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MMP2—bone cancer	0.000412	0.00163	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NDUFA12—bone cancer	0.000394	0.00156	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000389	0.00154	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—bone cancer	0.000368	0.00146	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CDK4—bone cancer	0.000362	0.00143	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MET—bone cancer	0.000362	0.00143	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000354	0.0014	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—SMO—bone cancer	0.000354	0.0014	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MET—bone cancer	0.000353	0.0014	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CDK4—bone cancer	0.000353	0.0014	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NT5C3A—bone cancer	0.00035	0.00139	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00035	0.00138	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO2—bone cancer	0.000344	0.00136	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000343	0.00136	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—CDK4—bone cancer	0.000341	0.00135	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000331	0.00131	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GRM4—bone cancer	0.000328	0.0013	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—RGS1—bone cancer	0.000328	0.0013	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NT5C3A—bone cancer	0.000327	0.00129	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	0.00032	0.00127	CbGpPWpGaD
Amantadine—DDC—Metabolism—DHFR—bone cancer	0.000319	0.00126	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MMP9—bone cancer	0.000318	0.00126	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MMP9—bone cancer	0.00031	0.00123	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP2—bone cancer	0.000302	0.0012	CbGpPWpGaD
Amantadine—DDC—Metabolism—GNA11—bone cancer	0.000298	0.00118	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GRM4—bone cancer	0.000297	0.00118	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RGS1—bone cancer	0.000297	0.00118	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000296	0.00117	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000295	0.00117	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP2—bone cancer	0.000294	0.00116	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO2—bone cancer	0.000289	0.00115	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000287	0.00114	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GRM1—bone cancer	0.000284	0.00113	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP3A4—bone cancer	0.00027	0.00107	CbGpPWpGaD
Amantadine—MAOB—Metabolism—DHFR—bone cancer	0.000268	0.00106	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000268	0.00106	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—BRAF—bone cancer	0.000263	0.00104	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GRM1—bone cancer	0.000258	0.00102	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—bone cancer	0.000257	0.00102	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000255	0.00101	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GNA11—bone cancer	0.000251	0.000993	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—bone cancer	0.00025	0.000992	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BRAF—bone cancer	0.000245	0.00097	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NDUFA12—bone cancer	0.000231	0.000915	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTP1—bone cancer	0.000231	0.000915	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP3A4—bone cancer	0.000227	0.0009	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP9—bone cancer	0.000227	0.000898	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP9—bone cancer	0.000221	0.000876	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MDM2—bone cancer	0.00022	0.000872	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00022	0.00087	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—JUN—bone cancer	0.00022	0.00087	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MDM2—bone cancer	0.000205	0.000813	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTP1—bone cancer	0.000194	0.00077	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NT5C3A—bone cancer	0.000191	0.000758	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—bone cancer	0.000183	0.000726	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GNA11—bone cancer	0.000183	0.000725	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—SMO—bone cancer	0.000182	0.00072	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—bone cancer	0.000179	0.000708	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RGS1—bone cancer	0.000176	0.000696	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GRM4—bone cancer	0.000176	0.000696	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GNA11—bone cancer	0.000166	0.000658	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL3—bone cancer	0.000166	0.000657	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000163	0.000645	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000157	0.000622	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO2—bone cancer	0.000153	0.000608	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GRM1—bone cancer	0.000152	0.000604	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL3—bone cancer	0.000151	0.000597	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—bone cancer	0.000145	0.000574	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO2—bone cancer	0.000143	0.000567	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—DHFR—bone cancer	0.000142	0.000564	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000142	0.000561	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNA11—bone cancer	0.000133	0.000527	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—DHFR—bone cancer	0.000133	0.000526	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNA11—bone cancer	0.000124	0.000491	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP3A4—bone cancer	0.000121	0.000478	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—bone cancer	0.00012	0.000474	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP3A4—bone cancer	0.000112	0.000445	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000111	0.000441	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMO—bone cancer	0.000107	0.000425	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTP1—bone cancer	0.000103	0.000409	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—bone cancer	0.000101	0.000399	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNA11—bone cancer	9.82e-05	0.000389	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTP1—bone cancer	9.62e-05	0.000381	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.35e-05	0.00037	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ATF1—bone cancer	9.13e-05	0.000362	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL3—bone cancer	8.9e-05	0.000353	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—bone cancer	8.38e-05	0.000332	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—DHFR—bone cancer	7.78e-05	0.000308	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFBR2—bone cancer	7.61e-05	0.000302	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNA11—bone cancer	7.27e-05	0.000288	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1R—bone cancer	7.16e-05	0.000284	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP3A4—bone cancer	6.59e-05	0.000261	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTP1—bone cancer	5.64e-05	0.000223	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—bone cancer	5.34e-05	0.000212	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KIT—bone cancer	5.2e-05	0.000206	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—bone cancer	4.98e-05	0.000197	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—bone cancer	4.88e-05	0.000193	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—bone cancer	4.73e-05	0.000187	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—bone cancer	4.09e-05	0.000162	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JUN—bone cancer	3.56e-05	0.000141	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—bone cancer	3.46e-05	0.000137	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—bone cancer	2.92e-05	0.000116	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—bone cancer	2.8e-05	0.000111	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—bone cancer	2.35e-05	9.3e-05	CbGpPWpGaD
